[{"indications": "Indications\u00a0mild to moderate essential hypertension", "name": "MOXONIDINE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.5 Hypertension and heart failure", "2.5.2 Centrally acting antihypertensive drugs", "MOXONIDINE"], "cautions": "Cautions\u00a0avoid abrupt withdrawal (if concomitant treatment with beta-blocker has to\r\nbe stopped, discontinue beta-blocker first, then moxonidine after a few days); severe coronary artery\r\ndisease; unstable angina; first-degree AV block; moderate heart\r\nfailure; interactions: see Appendix\r\n1 (moxonidine)", "side-effects": "Side-effects\u00a0dry mouth, diarrhoea, nausea, vomiting, dyspepsia,\r\ndizziness, somnolence, insomnia, back pain, rash, pruritus; less commonly bradycardia, tinnitus, angioedema, oedema,\r\nnervousness, neck pain", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129030.htm", "doses": ["200\u00a0micrograms once daily in the morning, increased if\r\nnecessary after 3 weeks to 400\u00a0micrograms daily in 1\u20132 divided doses;\r\nmax. 600\u00a0micrograms daily in 2 divided doses (max. single dose 400\u00a0micrograms)"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014no information available"}]